Grifols Stock (BME:GRF)


Today's Range
€16.55 - €16.97
52-Week Range
€15.08 - €25.94
Market Cap

About Grifols (BME:GRF)


Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Show more

GRF Stock Price

Statistics Highlights (BME:GRF)

Shares Outstanding 426.13M Beta 0.19
Public Float 550.50M P/E Ratio 17.46
% Short of Float - Dividend (Yield) 0.36 (0.02%)
Held by Insiders 30.57% Ex-Dividend Date Jun 3, 2021
Held by Institutions 38.01% IPO Date -

GRF Financial Summary

Dec 20 Dec 19 Dec 18
Revenue €5.34B €5.10B €4.49B
EBITDA €1.42B €1.44B €1.23B
Net Income €708.99M €625.15M €596.64M
Total Assets €15.27B €15.54B €12.48B
Total Cash €579.65M €741.98M €1.03B
Total Debt
Jun 21 Mar 21 Dec 20
Revenue €1.35B €1.18B €1.31B
EBITDA €241.90M €286.15M €374.52M
Net Income €136.88M €129.94M €223.31M
Total Assets €16.21B €16.14B €15.27B
Total Cash €397.86M €380.98M €579.65M
Total Debt

GRF Stock Price History

Grifols Annual Stock Price History

Year Open Close Change
2022 €16.77 €16.92 0.86%
2021 €24.02 €16.77 -30.18%
2020 €31.60 €24.02 -23.99%

Grifols Daily Stock Price History

Date Open High Low Close Change Volume
Jan 21, 2022 €16.92 €17.09 €16.56 €16.62 -3.01% 1.20M

(BME:GRF) Stock Price FAQs

What is today's stock price of Grifols (BME:GRF)?

  • The current stock price of Grifols (BME:GRF) is €16.92.
  • Today GRF stock price opened at €16.62 after previous close of €16.63.
  • During the day, Grifols stock quote has varied from a low of €16.55 to a high of €16.97.

What is Grifols's 52-week change?

  • GRF 52-week high stock quote is €25.94, which is 53.40% above the current share price.
  • The Grifols (BME:GRF) 52-week low stock price is €15.08, which is 10.80% below the current share price.
  • Grifols share price volatility (52-week beta) is 0.19.

Grifols (BME:GRF) FAQ

How Much is Grifols Worth?

Grifols's worth today based on market capitalisation is €10.07B

How much dividend does Grifols Pay?

The current annualized dividend payout for GRF stock is €0.36, the dividend yield is 2.19% and the payout ratio is 47.30%.
View More Details on Grifols's "Dividend" Section

When is the next earnings date for Grifols (BME:GRF)?

Grifols is expected to report earnings on May 02 ,2022.
View More Details on Grifols's 'Earnings' Section

What is Grifols’s Price to Earning (PE) ratio?

Grifols has a Price to Earning (P/E) ratio of 17.46. GRF stock also has a Price to Sales (P/S) ratio of 1.94, a Price to Book of 2.05 and Price/Earnings to Growth (PEG) of 3.83.

What is the Grifols's ticker?

Grifols trades on the Madrid stock market in Spain under the ticker symbol "GRF". Grifols’s stock symbol can also be displayed as "BME:GRF".

Who are the owners of Grifols?

Grifols (BME:GRF) is owned by 38.01% institutional shareholders and by 30.57% insiders. The rest is owned by the public.
Explore More Details on Grifols's “Ownership” Section

Who are the key executives of Grifols (GRF)?

Grifols's key executive team includes the following managers:

  • Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (1964)
  • Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (1977)
  • Mr. Alfredo Arroyo Guerra, CFO & VP (1958)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs (NA)
  • Ms. Nuria Pascual Lapeña, VP of Corp. Treasury & Investor Relations (1964)
  • Mr. David Ian Bell, Gen. Counsel & Chief Corp. Devel. Officer (1955)
  • Ms. Maria Teresa-Rioné Llano, VP of Corp. Communications (1966)
  • Mr. Mateo Florencio Borrás Humbert, Corp. VP & Chief HR Officer (1956)
  • Mr. Francisco Javier Jorba Ribes, Corp. VP and Pres of the Biological Industrial Group (1951)
  • Mrs. Montserrat Lloveras Calvo, Corp. VP and Director of Corp. Accounting & Reporting (1962)

What is Grifols’s Sector & Industry Classification?

Grifols (BME:GRF) is classified under the "Healthcare" sector and under the "Drug Manufacturers-General" industry.

What is the ESG rating for Grifols (BME:GRF) ?

ESG scores assess the degree to which a company’s enterprise business value is at risk driven by environmental, social, and governance issues. The scores are a measure of risk on an absolute scale of 0-100, with a lower score meaning less risk.

GRF’s total ESG score is 27.07. The company’s environmental score is 3.04, social score is 21.71 and governance score is 11.83.
Grifols (BME:GRF) is involved in the following activities (which decreases its ESG score) : "animalTesting", "catholic".

How many employees work for Grifols?

Currently the number of employees working for Grifols is 23,431.

Where are Grifols's Headquarters?

Grifols (BME:GRF) is headquartered in Spain.

What are Grifols's Address and Phone Number?

Grifols’s mailing address is Avinguda de la Generalitat, 152, Barcelona, Spain, 08174.
The company’s phone number is 34 93 571 00 00.

What is the official website for Grifols?

Grifols’s official website is